ORIGINAL ARTICLE
The relationship of tumour-associated macrophages (CD68, CD163, CD11c) and cancer stem cell
(CD44) markers with prognostic parameters in breast carcinomas
1
Department of Pathology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Turkey
2
Department of General Surgery, Faculty of Medicine, Afyonkarahisar Health Sciences University, Turkey
Submission date: 2022-04-21
Final revision date: 2022-11-21
Acceptance date: 2022-12-07
Publication date: 2023-03-03
Corresponding author
Çiğdem Özdemir
Çiğdem Özdemir, MD Department of Pathology Faculty of Medicine Afyonkarahisar Health Sciences University Afyonkarahisar, Turkey
Çiğdem Özdemir, MD Department of Pathology Faculty of Medicine Afyonkarahisar Health Sciences University Afyonkarahisar, Turkey
Pol J Pathol 2022;73(4):299-309
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In invasive breast cancer (IBC), tumour-associated macrophages and cancer stem cells in the tumour microenvironment are thought to be associated with poor prognosis, tumour growth, and metastasis.
Material and methods:
In this study, we evaluated the relationship of CD68, CD163, CD11c, and CD44 expressions in the tumour microenvironment of IBC with prognostic parameters by immunohistochemical method.
Results:
A correlation was found between high histological grade, oestrogen receptor/ progesterone receptor negativity, and high Ki-67 index in IBC, and the number of CD68-, CD163-, and CD11c-positive macrophages in the tumour microenvironment. In addition, in the tumour microenvironment, a correlation was found between IBC-specific subtypes and CD68, luminal A subtype relative to luminal B and CD163, HER2 score 3 cases, and CD11c-positive macrophage count. It was observed that CD44 expression in the tumour in IBC was not associated with the parameters examined. In addition, a high-level linear correlation was found between CD68- and CD163- and CD11c-positive macrophage counts. Tumour-associated macrophages in the tumour microenvironment in IBC may be a novel prognostic factor and an alternative avenue for targeted therapies.
Conclusions:
The fact that CD44 positivity in the tumour is not associated with prognostic parameters will contribute to the literature in this direction.
In invasive breast cancer (IBC), tumour-associated macrophages and cancer stem cells in the tumour microenvironment are thought to be associated with poor prognosis, tumour growth, and metastasis.
Material and methods:
In this study, we evaluated the relationship of CD68, CD163, CD11c, and CD44 expressions in the tumour microenvironment of IBC with prognostic parameters by immunohistochemical method.
Results:
A correlation was found between high histological grade, oestrogen receptor/ progesterone receptor negativity, and high Ki-67 index in IBC, and the number of CD68-, CD163-, and CD11c-positive macrophages in the tumour microenvironment. In addition, in the tumour microenvironment, a correlation was found between IBC-specific subtypes and CD68, luminal A subtype relative to luminal B and CD163, HER2 score 3 cases, and CD11c-positive macrophage count. It was observed that CD44 expression in the tumour in IBC was not associated with the parameters examined. In addition, a high-level linear correlation was found between CD68- and CD163- and CD11c-positive macrophage counts. Tumour-associated macrophages in the tumour microenvironment in IBC may be a novel prognostic factor and an alternative avenue for targeted therapies.
Conclusions:
The fact that CD44 positivity in the tumour is not associated with prognostic parameters will contribute to the literature in this direction.
REFERENCES (49)
1.
Board. WcoTE. Breast Tumours. WHO classification of tumors neWHOG, Switzerland 2019.
2.
Özmen V, Özmen T, Doğru V. Breast cancer in Turkey; an analysis of 20.000 patients with breast cancer. Eur J Breast Health 2019; 15: 141.
3.
Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY. Tumor- associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer 2019; 22: 38-51.
4.
Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012; 12: 1-9.
5.
Mahmoud S, Lee A, Paish E, Macmillan R, Ellis I, Green A. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 2012; 65: 159-63.
6.
Lewis C, Leek R, Harris A, McGee JD. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 1995; 57: 747-751.
7.
Can NY, Ayturk S, Celik M, et al. Histological perspective on the effects of tumor-associated macrophages in the tumor microenvironment surrounding papillary thyroid carcinoma. Pol J Pathol 2016; 67: 332-344.
8.
Tiainen S, Tumelius R, Rilla K, et al. High numbers of macrophages, especially M2-like (CD 163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 2015; 66: 873-883.
9.
Ramanathan S, Jagannathan N. Tumor associated macrophage: a review on the phenotypes, traits, and functions. Iran J Cancer Prev 2014; 7: 1.
10.
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system is in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
11.
Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 2017; 114: 206-221.
12.
Mantovani A, Sica A. Macrophages, innate immunity, and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-237.
13.
Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer 2017; 117: 1583-1591.
14.
Ni C, Yang L, Xu Q, et al. CD68-and CD163-positive tumor infiltrating macrophages in non-metastatic breast cancer: a retrospective study and meta-analysis. J Cancer 2019; 10: 4463.
15.
Munir MT, Kay MK, Kang MH, et al. Tumor-associated macrophages as multifaceted regulators of breast tumor growth. Int J Mol Sci 2021; 22: 6526.
16.
Campbell MJ, Tonlaar NY, Garwood ER, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011; 128: 703-711.
17.
Mou W, Xu Y, Ye Y, et al. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment. Cancer Lett 2015; 358: 115-123.
18.
De Beça FF, Caetano P, Gerhard R, et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Cinical Pathol 2013; 66: 187-191.
19.
Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol 2015; 13: 56.
20.
Qiu Y, Pu T, Guo P, et al. ALDH+/CD44+ cells in breast cancer are associated with worse prognosis and poor clinical outcome. Exp Mol Pathol 2016; 100: 145-150.
21.
Rabinovich I, Sebastião APM, Lima RS, et al. Cancer stem cell markers ALDH1 and CD44+/CD24-phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochem 2018; 62: 2943.
22.
Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-946.
23.
Xu H, Wu K, Tian Y, et al. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol 2016; 49: 1343-1350.
24.
Zhong Y, Shen S, Zhou Y, et al. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24-phenotype. Med Oncol 2014; 31: 864.
25.
Butti R, Gunasekaran VP, Kumar TV, Banerjee P, Kundu GC. Breast cancer stem cells: biology and therapeutic implications. Int J Biochem Cell Biol 2019; 107: 38-52.
26.
Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer 2017; 24: 3-15.
27.
Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 2018; 11: 64.
28.
Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol 2015; 13: 1-8.
29.
Bourguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 2001; 6: 287-297.
30.
Gyan E, Owiredu WK, Fondjo LA, Jackson AM, Green AR, Rahman GA. A review of the racial heterogeneity of breast cancer stem cells. Gene 2021; 796: 145805.
31.
Sanmartín E, Ortiz-Martínez F, Pomares-Navarro E, et al. CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. Virchows Arch 2017; 470: 81-90.
32.
Ma W, Deng Y, Zhou L. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol 2005; 17: 258-263.
33.
Morris S, McLaughlin R, McHale T, Connolly G, Given H. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study. Eur J Surg Oncol 2001; 27: 527-531.
34.
Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656-1664.
35.
Ryspayeva D, Smolanka I, Dudnichenko A, et al. Are CD44+/CD24– cells the assumed cancer stem cells in breast cancer? Exp Oncol 2017; 39: 224-228.
36.
Ma C, Komohara Y, Ohnishi K, et al. Infiltration of tumor- associated macrophages is involved in CD 44 expression in clear cell renal cell carcinoma. Cancer Sci 2016; 107: 700-707.
37.
Campbell I, Lao C, Blackmore T, et al. Surgical treatment of early stage breast cancer in the Auckland and Waikato regions of New Zealand. ANZ J Surg 2018; 88: 1263-1268.
38.
Witschen PM, Chaffee TS, Brady NJ, et al. Tumor cell associated hyaluronan-CD44 signaling promotes pro-tumor inflammation in breast cancer. Cancers 2020; 12: 1325.
39.
Zhao X, Qu J, Sun Y, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget 2017; 8: 30576.
40.
Esbona K, Yi Y, Saha S, et al. The presence of cyclooxygenase 2, tumor-associated macrophages, and collagen alignment as prognostic markers for invasive breast carcinoma patients. Am J Pathol 2018; 188: 559-573.
41.
Miyasato Y, Shiota T, Ohnishi K, et al. High density of CD 204-positive macrophages predicts worse clinical prognosis in patients with breast cancer. Cancer Sci 2017; 108: 1693-1700.
42.
Lee H, Lee HJ, Song IH, et al. CD11c-positive dendritic cells in triple-negative breast cancer. In Vivo 2018; 32: 1561-1569.
43.
Laforest S, Ennour-Idrissi K, Ouellette G, et al. Associations between markers of mammary adipose tissue dysfunction and breast cancer prognostic factors. Int J Obes 2021; 45: 195-205.
44.
Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y. Prognostic value of immune checkpoint molecules in breast cancer. Biosci Rep 2020; 40: BSR20201054.
45.
Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer 2015; 18: 740-750.
46.
Shu QH, Ge YS, Ma HX, et al. Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection. J Cell Mol Med 2016; 20: 1024-1035.
47.
Collina F, Di Bonito M, Li Bergolis V, et al. Prognostic value of cancer stem cells markers in triple-negative breast cancer. BioMed Res Int 2015; 2015.
48.
Wang J, Browne L, Slapetova I, et al. Multiplexed immunofluorescence identifies high stromal CD68+ PD-L1+ macrophages as a predictor of improved survival in triple-negative breast cancer. Sci Rep 2021; 11: 1-12.
49.
Zhang G, Guo L, Yang C, et al. A novel role of breast cancer- derived hyaluronan on inducement of M2-like tumor- associated macrophages formation. Oncoimmunol 2016; 5: e1172154.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
